Compare GNK & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNK | OMER |
|---|---|---|
| Founded | 2004 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 732.0M | 628.9M |
| IPO Year | 2005 | 2009 |
| Metric | GNK | OMER |
|---|---|---|
| Price | $18.77 | $11.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $19.00 | ★ $27.50 |
| AVG Volume (30 Days) | 568.7K | ★ 1.7M |
| Earning Date | 11-05-2025 | 11-13-2025 |
| Dividend Yield | ★ 7.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $331,332,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.34 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.20 | $2.95 |
| 52 Week High | $19.60 | $13.60 |
| Indicator | GNK | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 60.52 | 71.21 |
| Support Level | $18.64 | $9.31 |
| Resistance Level | $19.45 | $11.03 |
| Average True Range (ATR) | 0.40 | 0.65 |
| MACD | 0.01 | 0.17 |
| Stochastic Oscillator | 67.86 | 89.93 |
Genco Shipping & Trading Ltd is an international shipping company specializing in the transportation of iron ore, coal, grain, steel products and other drybulk cargoes. It is involved in the ocean transportation of drybulk cargoes. The company operates in one segment, with two reportable segment: Major and Minor bulk fleet. It generates revenue through time charter agreements, spot market voyage charters, pool agreements and spot market-related time charters. oyage revenues also include the sale of bunkers consumed during short-term time charters pursuant to the terms of the time charter agreement.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.